Skip to content
FidoCure®  logo — AI-enabled precision medicine platform for canine cancer: Fi...

FidoCure®

AI-enabled precision medicine platform for canine cancer: Fighting cancer on both ends of the leash.

Founded 2018 United States Palo Alto, United States 22 employees Venture round Total: $15.00M Health Care

General Information

Company Name FidoCure®
Founded Year 2018
Location United States Palo Alto, United States
Founders / Decision Makers
Team member
Employees 22
Industries Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with FidoCure® . To contact FidoCure® , visit fidocure.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does FidoCure® compare?

A PDF of FidoCure® and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting FidoCure® soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About FidoCure®

FidoCure® is an innovative startup in the field of Health Care with a mission to revolutionize the treatment of canine cancer. Their slogan, "AI enabled precision medicine platform for canine cancer: Fighting cancer on both ends of the leash," encapsulates their dedication to leveraging advanced technology for the well-being of our four-legged friends. The company, part of The One Health Company, has introduced the groundbreaking FidoCure® Next Generation DNA Sequencing Test, which utilizes individualized precision medicine to create tailored treatment plans for canine cancer patients. Notably, FidoCure has amassed the world's largest canine cancer genomics database, ensuring access to the latest advances in cancer care for pet dogs. Backed by prominent biotech investors including Polaris Ventures, A16Z, YCombinator, and their latest investment from Global Brain in the Venture Round investment at 19 July 2022, The One Health Company demonstrates its strong support and credibility in the industry. Their research has been published in prestigious journals such as Nature Precision Oncology Journal and Nature Scientific Reports, further establishing their authority and expertise in the field of veterinary oncology. With their innovative approach and strong financial backing, FidoCure is well-positioned to make a significant impact in the fight against canine cancer. For more information, visit www.fidocure.com.

Business keywords: Precision Medicine, Canine Cancer, Next Generation DNA Sequencing, Veterinary Oncology, Personalized Treatment, Canine Genomics, Cancer Care, Biotech, Investment, Technology, Peer-Reviewed Research, Medical Innovation, Venture Capital

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 1
Global Brain
19 Jul 2022
Venture Round Undisclosed 2
Spark Growth Ventures, Bossanova Investimentos
04 Mar 2022
Series A $10.00M 8
Lerer Hippeau, Y Combinator +6
29 Oct 2020
Non Equity Assistance Undisclosed 1
ic@3401
31 Jan 2019
Seed Round $5.00M 6
Lerer Hippeau, MaC Venture Capital +4
23 Jan 2019
Seed Round Undisclosed 1
Y Combinator
22 Mar 2018
Grant Undisclosed 1
Ben Franklin Technology Partners
31 Jan 2017

FidoCure® Alternatives & Competitors

View All Alternatives
FidoCure® vs
Aniling
Aniling Spain

Accelerating Epigenomics for Precision Medicine against cancer

Seed
12 employees
Biotechnology, Health Care
FidoCure® vs
OncoDNA
OncoDNA Belgium

Genomic and theranostic company specializing in precision medicine for the treatment of cancer and g...

Series C
52 employees
Biotechnology, Health Care
FidoCure® vs
Ashion Analytics
Ashion Analytics United States

We are an Exact Sciences sequencing-based Clinical laboratory. We tap into the power of the human ge...

3 employees
Biotechnology, Health Care

FAQ About FidoCure®

AI-enabled precision medicine platform for canine cancer: Fighting cancer on both ends of the leash.
FidoCure® was founded in 2018.
FidoCure® is headquartered in Palo Alto, United States.
FidoCure® operates in Health Care. Its work centres on Precision Medicine, Canine Cancer, Next Generation DNA Sequencing and Veterinary Oncology.
FidoCure® has approximately 22 employees.
FidoCure® has completed 7 funding rounds, raising a total of $15.00M. The latest funding stage is Venture round.
Top alternatives and competitors to FidoCure® include Aniling, OncoDNA, Ashion Analytics, Geneseeq Technology Inc., Syntekabio Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FidoCure® and Aniling are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for FidoCure® , https://bouncewatch.com/company/fidocure, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout